<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04730583</url>
  </required_header>
  <id_info>
    <org_study_id>2020P004137</org_study_id>
    <nct_id>NCT04730583</nct_id>
  </id_info>
  <brief_title>Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas</brief_title>
  <official_title>Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the tolerability and effectiveness of four FDA-approved treatments&#xD;
      in Neurofibromatosis Type 1 Cutaneous Neurofibromas. These treatments are: a 980nm laser, a&#xD;
      755nm laser, radio-frequency injection, and a Kybella injection. Each patient will have a&#xD;
      treatment and a control site.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>3 months after treatment</time_frame>
    <description>Device based treatment will be considered tolerable if &lt;40% of participants treated have a &gt;grade 2 adverse event (AE). A grade 2 AE is defined as an event that requires treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Report Outcomes</measure>
    <time_frame>For the 12 months after treatment</time_frame>
    <description>Using questionnaires we will determine the patients reported outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician Reported Outcomes</measure>
    <time_frame>For the 12 months after treatment</time_frame>
    <description>Using questionnaires we will determine the clinicians reported outcomes</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cutaneous Neurofibroma</condition>
  <arm_group>
    <arm_group_label>Kybella Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>980nm laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>755nm laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiofrequency</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kybella</intervention_name>
    <description>Injection into the cutaneous Neurofibromas lesion</description>
    <arm_group_label>Kybella Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>980nm laser</intervention_name>
    <description>Pulse laser at a wavelength of 980nm to the cutaneous Neurofibromas lesion</description>
    <arm_group_label>980nm laser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>755nm Alexandrite Laser</intervention_name>
    <description>Pulse laser at a wavelength of 755nm to the cutaneous Neurofibromas lesion</description>
    <arm_group_label>755nm laser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiofrequency</intervention_name>
    <description>Using an insulated micro-needle, the radio-frequency will be delivered to the cutaneous Neurofibromas lesion</description>
    <arm_group_label>Radiofrequency</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult males and females ≥18 years of age&#xD;
&#xD;
          -  Have a diagnosis of Neurofibromatosis Type 1&#xD;
&#xD;
          -  Patients must be seeking treatment for cutaneous Neurofibromas&#xD;
&#xD;
          -  Patients must have ≥ 6 paired cutaneous Neurofibromas (3 to be treated and 3&#xD;
             untreated) that are visible and measure between 2-4mm in size.&#xD;
&#xD;
          -  Able and willing to comply with all visit, treatment and evaluation schedules and&#xD;
             requirements&#xD;
&#xD;
          -  Able to understand and provide written informed consent&#xD;
&#xD;
          -  Access to a Smart Phone to be able to take and upload photographs to an application&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are undergoing other treatment modalities or investigational agents for&#xD;
             their cNF lesions&#xD;
&#xD;
          -  Individuals who cannot give informed consent or adhere to study schedule&#xD;
&#xD;
          -  Actively tanning during the course of the study&#xD;
&#xD;
          -  Adverse reactions to compounds of any external agent (e.g., gels, lotions or&#xD;
             anesthetic creams) required for use in the study, if no alternative to the said agent&#xD;
             exists;&#xD;
&#xD;
          -  Known allergy to injectable anesthetics or deoxycholic acid&#xD;
&#xD;
          -  Any condition which, in the Investigator's opinion, would make it unsafe (for the&#xD;
             participant or study personnel) to treat the participant as part of this research&#xD;
             study;&#xD;
&#xD;
          -  Pregnant females, due to possible discomfort with the procedure even though the&#xD;
             procedure is localized and there is no new drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Katie Vogel</last_name>
    <phone>617-724-2168</phone>
    <email>wellmancrc@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beverly Dammin</last_name>
    <email>bdammin@mgh.harvard.edu</email>
  </overall_contact_backup>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2021</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Richard Rox Anderson, MD</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Neurofibromatosis Type 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deoxycholic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

